CD8A and neoplasm: In the absence of a tumour, captopril significantly increased the proportion of CD8+ T lymphocytes (Figure 4a; 37.0% vs. 59.0%, control vs. treatment) while reducing the proportion of CD4+ and DN T lymphocytes (Figure 4a).